Genprex | MedPath

Genprex Secures Exclusive License for REQORSA Gene Therapy in Glioblastoma Treatment

17 days ago

• Genprex has entered into an exclusive patent license agreement with UTHealth Houston for its REQORSA gene therapy to treat glioblastoma, expanding beyond its established lung cancer applications. • Preclinical studies demonstrated that REQORSA significantly reduced glioblastoma cell viability and suppressed cancer cell migration by restoring TUSC2 expression, a novel tumor suppressor for this deadly brain cancer. • The agreement grants Genprex exclusive commercial rights to REQORSA for glioblastoma, addressing a significant unmet medical need for the most common and aggressive primary brain tumor in adults.

CS Diagnostics Partners with Lachman Consultants to Fast-Track FDA Approval for Novel Cancer Radiation Therapy Hydrogel

2 months ago

• CS Diagnostics (OTCQB: CSDX) has engaged regulatory experts Lachman Consultants to expedite FDA approval for CS-Protect Hydrogel, an innovative organ spacer device for radiation therapy, with approval expected within 3-4 months. • The CS-Protect Hydrogel technology represents a significant advancement in cancer radiotherapy by eliminating contamination risks and enabling more precise treatment delivery, addressing critical needs in oncology care. • Market potential for the technology appears substantial, with company executives noting that Boston Scientific previously acquired a similar product for $500 million, highlighting the commercial value of organ-sparing innovations in cancer treatment.

Genprex's Reqorsa Advances in Phase 2 Trial for Small Cell Lung Cancer

5 months ago

• Genprex's Acclaim-3 trial, evaluating Reqorsa with Tecentriq for extensive stage small cell lung cancer (ES-SCLC), has advanced to Phase 2. • The Phase 1 dose escalation showed a favorable safety profile, leading to the selection of 0.12 mg/kg as the Recommended Phase 2 Dose (RP2D). • The Phase 2 expansion will enroll approximately 50 patients to determine the 18-week progression-free survival rate. • Reqorsa, a gene therapy expressing the TUSC2 protein, has received Fast Track and Orphan Drug Designations from the FDA for SCLC treatment.

Cell and Gene Therapies Show Promise in Lung Cancer Treatment

7 months ago

• Kiromic BioPharma's Deltacel T-cell therapy demonstrates disease stabilization in NSCLC patients, showing potential in advanced solid tumor treatment. • Achilles Therapeutics advances neoantigen reactive T-cell therapy trials for NSCLC and melanoma, observing improved T-cell persistence with enhanced conditioning. • Genprex reports positive results in two lung cancer trials for Reqorsa gene therapy, while discontinuing another, focusing on optimal patient cohorts. • Viral immunotherapy combo CAN-2409 improves survival in NSCLC patients unresponsive to anti-PD-L1 therapy, reactivating exhausted immune systems.

Genprex's Reqorsa Shows Promise in Lung Cancer Gene Therapy; Uniphar Expands Commercialization Support

7 months ago

• Genprex presented positive preclinical data for Reqorsa, a gene therapy targeting Ras inhibitor-resistant lung cancer, mesothelioma, and glioblastoma, showing increased TUSC2 uptake in tumor cells. • Uniphar has launched its seventh cell and gene therapy program, integrating cross-functional teams to support the commercialization of complex therapies globally. • BioCardia, Inc. has completed its Phase III trial of CardiAMP, a cell therapy for ischemic heart failure, with results expected in early 2025, showing potential benefits in earlier trials.

Genprex and University of Michigan Partner to Study Reqorsa® Gene Therapy in ALK+ Lung Cancer

7 months ago

• Genprex has entered a sponsored research agreement with the University of Michigan to study Reqorsa® gene therapy combined with ALK-inhibitors for ALK+ lung cancer. • The collaboration includes ALK Positive, a patient-driven research organization, to improve outcomes for ALK-positive lung cancer patients. • Preclinical data suggests Reqorsa, which delivers the TUSC2 gene, induces apoptosis in ALK-inhibitor resistant NSCLC cell lines, supporting further clinical study. • ALK+ lung cancer affects younger individuals, and while ALK-targeted therapies exist, resistance develops, highlighting the need for new treatment strategies.

Genprex's Reqorsa Gene Therapy Advances to Highest Dose in Phase 1 SCLC Trial

7 months ago

• Genprex's Reqorsa, combined with Tecentriq, advances to the highest dose group (0.12 mg/kg) in Phase 1 of the Acclaim-3 trial for ES-SCLC after SRC approval. • The Phase 1 trial expansion demonstrated a favorable safety profile for Reqorsa with no dose-limiting toxicities observed in the 0.09 mg/kg dose group. • A patient in the trial experienced a partial remission, suggesting potential clinical benefit from Reqorsa in combination with Tecentriq for SCLC treatment. • The Acclaim-3 trial is now set to proceed to Phase 2, enrolling 50 patients to further evaluate the efficacy of Reqorsa and Tecentriq combination therapy.

Genprex Advances Reqorsa Gene Therapy for Mesothelioma Treatment

8 months ago

• Genprex is expanding its research program for Reqorsa, an investigational immunogene therapy, to include mesothelioma, a cancer with limited treatment options. • A Mesothelioma Clinical Advisory Board comprising world-renowned researchers has been formed to guide the development of Reqorsa for mesothelioma. • Reqorsa delivers the TUSC2 tumor suppressor gene via intravenous injection, showing promise in preclinical studies for mesothelioma, where TUSC2 expression is often reduced. • While expanding into mesothelioma, Genprex discontinued enrollment in the Acclaim-2 trial for NSCLC due to enrollment challenges amid a competitive clinical trial landscape.

Ractigen's RAG-18 Receives FDA Orphan Drug Designation for Duchenne and Becker Muscular Dystrophy

9 months ago

• Ractigen Therapeutics' RAG-18, a small activating RNA (saRNA) therapy, has been granted Orphan Drug Designation by the FDA for treating Duchenne and Becker muscular dystrophy. • RAG-18 previously received Rare Pediatric Disease Designation, making it the first saRNA therapy to achieve both designations, highlighting its potential for treating rare genetic conditions. • The therapy aims to increase utrophin production by targeting the UTRN gene, offering a functional substitute for the deficient dystrophin protein in DMD and BMD patients. • Preclinical data presented at OTS 2023 demonstrated RAG-18's ability to induce utrophin expression and ameliorate muscle damage in a mouse model of DMD.